ACHV — ACHIEVE LIFE SCIENCES, INC.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 949858 ·
Last close
$5.60
Market Cap
$574.89M
52W High
$6.16
52W Low
$2.62
ADV30
1,401,018
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,463,000 | -10,168,000 | 33,105,000 | 28,078,000 | 22,427,000 |
| Dec 2025 | 0 | — | -14,731,000 | -14,662,000 | 41,790,000 | 20,909,000 | 20,272,000 |
| Sep 2025 | 0 | — | -14,692,000 | -14,441,000 | 52,040,000 | 31,930,000 | 18,425,000 |
| Jun 2025 | 0 | — | -12,563,000 | -12,718,000 | 58,935,000 | 51,874,000 | 17,267,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,309,000
Investing CF
$9,034,000
Financing CF
$51,548,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.12
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-270,394,000
Inventory
—
Receivables
$0
ST Investments
$1,191,000
EBIT TTM
$-51,081,000
Pretax Income TTM
$-51,989,000
Interest Exp TTM
$908,000
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -54,880,000 | -54,648,000 | 41,790,000 | 20,272,000 | — | -49,465,000 |
| Dec 2024 | 0 | -39,069,000 | -39,827,000 | 38,633,000 | 17,734,000 | — | -29,770,000 |
| Dec 2023 | 0 | -27,250,000 | -29,815,000 | 19,371,000 | 20,819,000 | — | -24,479,000 |
| Dec 2022 | 0 | -40,800,000 | -42,350,000 | 29,971,000 | 21,668,000 | — | -37,569,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.46
Max Pain — expiry 2026-06-18
max pain strike: $5.00 · spot: $5.55 · call oi: 15,815 · put oi: 523
Expected Move to 2026-06-18:
±$0.73
(13.05%) —
implied range
$4.83 –
$6.28
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NNNN | Anbio Biotechnology | $737.81M | $16.81 | — |
| NRC | NRC HEALTH | $412.65M | $18.31 | — |
| MYGN | MYRIAD GENETICS INC | $408.02M | $4.32 | — |
| QDEL | QuidelOrtho Corp | $993.54M | $14.57 | — |
| OABI | OmniAb, Inc. | $305.89M | $2.11 | — |
News headlines (Yahoo Finance, 1h cache)
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
2026-06-02 12:30 · Yahoo
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
2026-05-19 18:15 · Yahoo
ACHV: CEO Enlists New Commercialization Team
2026-05-13 08:30 · Yahoo
Achieve Life Sciences Inc (ACHV) Q1 2026 Earnings Call Highlights: Strategic Financing and ...
2026-05-12 23:04 · Yahoo
Achieve Life Sciences, Inc. Q1 2026 Earnings Call Summary
2026-05-12 16:55 · Yahoo
Achieve Life Sciences Q1 Earnings Call Highlights
2026-05-12 14:08 · Yahoo
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
2026-05-12 11:05 · Yahoo
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 11:00 · Yahoo
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026
2026-05-05 12:30 · Yahoo
ACHV: Change of Command Brings Material Funding
2026-04-28 09:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.